Abstract: A refresh control circuit includes: a count flag circuit configured to generate and output a count flag signal at an active level based on a refresh activation signal when an all-bank refresh flag signal and a same-bank refresh flag signal are active; a count processing circuit configured to receive the count flag signal and count based on the count flag signal to generate a counting result; and a first control circuit configured to receive the counting result and generate and output, when the counting result is within a first preset range, a supplementary refresh indication signal at an active level. The supplementary refresh indication signal, when active, indicates that an associated memory performs a supplementary refresh operation.

Abstract: A bracket for mounting a light strip on a surface. The bracket comprises two components each with a light strip holder. A light strip path is defined between both light strip holders. The bracket comprises a hinge connecting the two components and enabling them to swing towards one another. The hinge and both components avoid light strip path when the components swing towards one another.

Abstract: A bracket for mounting a light strip on a surface. The bracket comprises two components each with a light strip holder. A light strip path is defined between both light strip holders. The bracket comprises a hinge connecting the two components and enabling them to swing towards one another. The hinge and both components avoid light strip path when the components swing towards one another.

Abstract: An electronic device has an elongate printed circuit substrate arrangement and a row of electrical units on the elongate printed circuit substrate arrangement. An indicator unit is wireless powered for identifying a particular location of the elongate printed circuit substrate arrangement. This identification is used for identifying the correct location for subsequent processing of the device during manufacture.

Abstract: A refresh control structure includes a processing circuit and a counter circuit. The processing circuit is configured to refresh a to-be-refreshed address based on a refresh window. The counter circuit is configured to generate the to-be-refreshed address, and control, based on a counter clock, the generated to-be-refreshed address to be incremented by 1. The counter circuit is further configured to reset a lowest bit of the to-be-refreshed address based on an abort signal, and in a process of resetting the lowest bit of the to-be-refreshed address, maintain a second lowest bit of the to-be-refreshed address unchanged. The present disclosure is configured to at least improve self refresh accuracy of the memory.

Abstract: A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.

Abstract: The present invention relates an elevating apparatus based on a hetero-oriented non-isometric, dual-spiral drive structure, comprising a first carrier and a second carrier, further comprising a first support and a second support that are telescoped together in a manner that they can rotate with respect to each other, the first support is provided with a first recessed portion and a first raised portion that shares the same spiral direction and spiral pitch, the second support is provided with a homo-oriented, isometric, dual-spiral second recessed portion that has a spiral direction different from that of the first recessed portion. The carrier of the present invention is provided in a simply-supported-beam, and the carrier force can be achieved without additional weight, and the operation is stable and reliable.

Abstract: A novel dry powder inhaler. By providing a plurality of capsule chambers (1a, 1b, 1c, 1d) arranged in parallel in a capsule dry powder inhalation device, a medicine dispenser containing active components of a composite product or their mixture separately is provided. The dry powder inhaler has a simple structure and is convenient to operate. In addition, the parameters of air inlet channels and an air outlet channel can be adjusted by means of each capsule chamber (1a, 1b, 1c, 1d) according to the properties of powder of a medicine or a combination, so as to provide an appropriate particle distribution for each active component.

Abstract: A rate negotiation method is provided. A first device switches a fiber transmission rate of a first port of the first device to a first fiber transmission rate based on a preset switching direction within a rotation period of a first fiber transmission rate set. The first device sends a negotiation packet to a second device through the first port of the first device within a duration of the first fiber transmission rate. If a response packet is received from the second device through the first port of the first device within the duration of the first fiber transmission rate, the first port of the first device is controlled to communicate with the second device based on the first fiber transmission rate.

Abstract: The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area ?10 m2/g and a particle-size distribution of X50?50 ?m and/or X90?500 ?m, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.

Abstract: Disclosed are a pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance. The pharmaceutical composition includes a therapeutically effective amount of a short peptide and morphine as active ingredients, and a pharmaceutically-acceptable carrier. The short peptide is a peptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or a pharmaceutically-acceptable salt thereof. In the method, the short peptide and morphine are administered to a subject simultaneously; or the short peptide is injected to the subject followed by administration of the morphine; or a pharmaceutical composition including the short peptide and morphine is administered to the subject.

Abstract: A pharmaceutical composition of a tricyclic PDE3/PDE4 dual inhibitor compound and a preparation method therefor, specifically relating to a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, and use thereof

Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Abstract: A solid pharmaceutical composition comprising a quinazoline derivative or a medicinal salt thereof, and a preparation method therefor. Specifically, provided is a solid pharmaceutical composition comprising N6-(1-acryloylpiperidin-4-yl)-N4-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine or a medicinal salt thereof, and a preparation method therefor and use thereof.

Abstract: The present invention relates an elevating apparatus based on a hetero-oriented non-isometric, dual-spiral drive structure, comprising a first carrier and a second carrier, further comprising a first support and a second support that are telescoped together in a manner that they can rotate with respect to each other, the first support is provided with a first recessed portion and a first raised portion that shares the same spiral direction and spiral pitch, the second support is provided with a homo-oriented, isometric, dual-spiral second recessed portion that has a spiral direction different from that of the first recessed portion. The carrier of the present invention is provided in a simply-supported-beam, and the carrier force can be achieved without additional weight, and the operation is stable and reliable.

Abstract: Disclosed are a pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance. The pharmaceutical composition includes a therapeutically effective amount of a short peptide and morphine as active ingredients, and a pharmaceutically-acceptable carrier. The short peptide is a peptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or a pharmaceutically-acceptable salt thereof. In the method, the short peptide and morphine are administered to a subject simultaneously; or the short peptide is injected to the subject followed by administration of the morphine; or a pharmaceutical composition including the short peptide and morphine is administered to the subject.